|Print Page Close Window|
Aptevo Therapeutics and the ADAPTIR™ (Modular Protein Technology) Platform: The Future of Immuno-oncology
Aptevo Therapeutics is a biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Our core technology is the ADAPTIR™ (modular protein technology) platform. We also have four commercial products that generate revenue in the areas of hematology and infectious diseases, as well as various investigational stage product candidates in immuno-oncology.
Stock Details Stock Summary | APVO | Nasdaq $3.98 - 0.21 (5.01%)
Updated December 14, 2017 4:00 p.m. ET
30th Annual ROTH Conference
American Society of Hematology 59th Annual Meeting
29th Annual Piper Jaffray Healthcare Conference
© Aptevo BioTherapeutics, LLC.